EIGER BIOPHARMACEUTICALS, INC. — Net Income by Fiscal Year
12 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/a48f7794-c40f-4de2-80b1-d449207f640d/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2023 | $-75.0M | 2023-01-01 – 2023-12-31 | evidence 0001628280-24-015297 |
| FY 2022 | $-96.8M | 2022-01-01 – 2022-12-31 | evidence 0001305253-23-000005 |
| FY 2021 | $-33.9M | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-009697 |
| FY 2020 | $-65.1M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-011758 |
| FY 2019 | $-70.3M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-010645 |
| FY 2018 | $-52.4M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-007830 |
| FY 2017 | $-42.4M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-005123 |
| FY 2016 | $-47.1M | 2016-01-01 – 2016-12-31 | evidence 0001564590-17-005079 |
| FY 2015 | $-13.3M | 2015-01-01 – 2015-12-31 | evidence 0001564590-17-005079 |
| FY 2014 | $-1.5M | 2014-01-01 – 2014-12-31 | evidence 0001564590-17-005079 |
| FY 2013 | $-119.7M | 2000-12-21 – 2014-03-31 | evidence 0001193125-14-197051 |
| FY 2012 | $-15.7M | 2012-01-01 – 2012-12-31 | evidence 0001193125-15-112793 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
EIGER BIOPHARMACEUTICALS, INC. — all facts · Revenue · Operating Income